Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Research 1990, 50: 6302-10. PMID: 2205379.Peer-Reviewed Original ResearchConceptsLymphokine-activated killer cellsRecombinant interleukin-2LAK activityIL-2Killer cellsDose levelsMononuclear cellsUnits/m2 body surface areaIntraperitoneal recombinant interleukin-2M2 body surface areaLAK/ILOvarian cancer refractorySerum IL-2Less IL-2Dose-limiting toxicityPhase I trialIL-2 levelsAdditional IL-2IL-2-dependent cell lineBody surface areaSignificant weight gainMononuclear cell collectionPeripheral blood cellsHighest dose levelCancer refractory